SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOHN W. who wrote (1921)9/30/1997 11:48:00 AM
From: James Silverman   of 6136
 
John,
To stick up for Henry here in an open and civil fashion, he merely posted an extremely relevant article to AGPH and protease inhibitors as a drug class. If anyone thinks that resistance is not an extremely serious variable in the future lifecycle of Viracept, Crix and the rest of them, they are mistaken. The question is not "if" resistance will become prevalent, its a question of how widespread and how fast. This is not a negative spin, this is the reality of AIDS and protease inhibitors. To properly value AGPH, this needs to be taken into consideration along with all the positives frequently highlighted.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News